|Bid||86.75 x 1000|
|Ask||89.90 x 800|
|Day's Range||87.07 - 88.40|
|52 Week Range||42.62 - 88.60|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 30, 2018 - Aug 3, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||83.58|
The potential for significant growth at these companies may be underappreciated by Wall Street analysts, and that could make them smart stocks to buy.
CNBC’s Erin Black, who has Type 1 Diabetes, puts the Dexcom G6 to the test to see if it’s as accurate as previous glucose monitors that require a finger prick and blood.
Abbott Laboratories (ABT) received FDA approval for its breakthrough CGM (continuous glucose monitoring) device, Freestyle Libre, in September 2017. For further details, please read Abbott’s Breakthrough CGM Device Freestyle Libre Wins FDA Approval. The company received reimbursement approval for the device from the Centers for Medicare & Medicaid Services in January 2018.
On a per-share basis, the San Diego-based company said it had a loss of 28 cents. Losses, adjusted for non-recurring gains, came to 32 cents per share. The results met Wall Street expectations. The average ...
NEW YORK, April 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Stock Monitor: Cancer Genetics Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 10, 2018 / Active-Investors.com has just released a free earnings report on DexCom, Inc. (NASDAQ: DXCM ). If you want ...
DexCom, Inc. today announced that it plans to release its first quarter 2018 financial results after market close on Wednesday, May 2, 2018. Management will hold a conference call to review the company's first quarter 2018 performance starting at 4:30 p.m.
Jim Cramer shares his take on callers' favorite stocks at lightning speed, including a pharmacy operator's stock.
DexCom, Inc. , the leader in continuous glucose monitoring is pleased to announce that the U.S. Food and Drug Administration has granted a De Novo request for the Dexcom G6® CGM System, the newest generation of CGM for people with diabetes ages 2 and up.
The U.S. Food and Drug Administration on Tuesday approved DexCom Inc's monitoring system to check blood sugar levels in children and adults suffering from diabetes, which can be used along with devices such as insulin pumps. This is the first glucose monitoring system permitted by the agency that can be used with other compatible medical devices, the FDA said. A previous version of DexCom's monitoring system had received FDA approval in 2016 but was not designed to be used with other devices.
NEW YORK, NY / ACCESSWIRE / March 26, 2018 / Rising concerns over a potential trade war with China continued to drag markets down on Friday, with the Dow Jones plummeting more than 400 points. The Dow ...
On February 26, 2018, Medtronic (MDT) announced that the FDA has approved a new arm indication for its Guardian Sensor 3, the latest and most accurate CGM (continuous glucose monitoring) sensor. The expanded indication will enable the sensor to be worn on the upper arm, thus providing more flexibility, higher accuracy, and enhanced performance. It is the only sensor approved for use with Medtronic’s MiniMed 670G, which is the first HCL (hybrid closed loop) insulin delivery system in the world.
On February 21, 2018, Medtronic (MDT) announced the launch of its MiniMed Mio Advance infusion set, the newest addition to its portfolio of MiniMed infusion sets. The device is used for insulin delivery from an insulin pump to a person’s body. In late 2018, Medtronic plans to expand the commercial availability of the device in other geographies around the world.